A Phase 4, Open-label Study to Evaluate Persistence of the Antibody Response Elicited by Prevenar in Healthy Children in China Who Have Been Previously Immunized With a 4-dose Series of a Pneumococcal Conjugate Vaccine During Infancy in Study 0887x-101518

Trial Profile

A Phase 4, Open-label Study to Evaluate Persistence of the Antibody Response Elicited by Prevenar in Healthy Children in China Who Have Been Previously Immunized With a 4-dose Series of a Pneumococcal Conjugate Vaccine During Infancy in Study 0887x-101518

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Oct 2016

At a glance

  • Drugs Pneumococcal 7-valent CRM197 vaccine conjugate (Primary) ; DTaP vaccine
  • Indications Pneumococcal infections
  • Focus Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 28 Oct 2016 New trial record
    • 08 Sep 2016 Results assessing long-term antibody persistence (3 years after last dose), published in the Vaccine Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top